Oxbryta (voxelotor) Events

Muyiwa

Father, bongo player, and actual Oxbryta patient

Webinar

09/27/2022

12:00 PM ET

September National Sickle Cell Awareness Month

Sickle Cell Disease Association of America, St. Petersburg Chapter, FL

Nirmish Shah, MD

Director, Sickle Cell Transition Program, Duke University

Call (732) 969-5000 x157

To register, please fill out the information below. These programs are for US residents only.

*Required field.

First name* Last name* Email address* Zip code* Address Address 2 City* State* Please select which best applies to you.* How did you hear about this program?*

I am a US resident at least 18 years old or will be accompanied by a parent or guardian over 18, and the information is accurate to the best of my knowledge.*

I’d like to receive information on resources and products from Oxbryta.

By submitting this form, you agree to allow Oxbryta and its agents to collect the information provided and to be contacted directly by an Oxbryta representative. Your information will not be used for any other purpose than for a representative to respond to your information request or for us to send you other updates if you have registered to receive them. Oxbryta will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Oxbryta and its agents. Oxbryta will only use your information in accordance with its Privacy Policy.

SIGN UP FOR EDUCATIONAL EVENTS ABOUT OXBRYTA

IMPORTANT SAFETY INFORMATION AND INDICATION

Do not take OXBRYTA if you or your child have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.

Before taking OXBRYTA, tell your healthcare provider about all of your medical conditions, including if you or your child:

have liver problems
are pregnant or plan to become pregnant. It is not known if OXBRYTA can harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if OXBRYTA can pass into your breastmilk and if it can harm your baby. Do not breastfeed during treatment with OXBRYTA and for at least 2 weeks after the last dose.

Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work and may affect the results of certain blood tests. Keep a list of all your medicines and show it to your healthcare provider.

What should I avoid while taking OXBRYTA?

Do not take St. John’s wort during treatment with OXBRYTA.

What are the possible side effects of OXBRYTA?

OXBRYTA can cause serious side effects, including:

Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:

rash
hives

shortness of breath (difficult breathing)
swelling of the face

The most common side effects of OXBRYTA include:

headache
diarrhea
stomach-area (abdominal) pain

nausea
rash or hives
fever

The most common side effects of OXBRYTA in children ages 4 to less than 12 years of age include:

fever
vomiting
rash

stomach-area (abdominal) pain
diarrhea
headache

These are not all the possible side effects of OXBRYTA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).

Keep OXBRYTA and all medicines out of the reach of children.

INDICATION

What is OXBRYTA?

OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 4 years of age and older.

It is not known if OXBRYTA is safe and effective in children with sickle cell disease below 4 years of age.

This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Oxbryta^®, GBT Source^®, GBT Source Solutions^® are registered trademarks of Global Blood Therapeutics, Inc., a wholly owned subsidiary of Pfizer Inc. All other trademarks are the property of their respective owners.

© 2023 Pfizer Inc. All Rights Reserved. P-VOX-US-00098 v9

This site is intended for residents of the United States, Puerto Rico, and US territories.

MORE Back to top

Stay in the know

Receive additional information on Oxbryta and sickle cell.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit MedWatch: FDA Safety Information & Adverse Event Reporting Program or call 1-800-FDA-1088.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2023 Pfizer Inc. All Rights Reserved.Terms of Use Privacy Policy Sitemap